 Momenta Pharmaceuticals NASDAQ:MNTAs stock had its buy rating reaffirmed by Stifel Nicolaus in a report issued on Wednesday, TipRanks reports. Several other analysts also recently commented on MNTA. Wells Fargo Co upped their price objective on shares of Momenta Pharmaceuticals from 40.00 to 48.00 and gave the company an overweight rating in a report ... 